Kodiak Sciences (KOD) will present first scientific data from Phase 3 DAYBREAK (wet AMD), Phase 3 GLOW2 (diabetic retinopathy), and Phase 1b APEX (MESI) at AAO 2026. DAYBREAK previously met its primary endpoint.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
